FDA Approves RAMIPRIL — Lupin Pharmaceuticals, Inc.

Lupin Pharmaceuticals announced yesterday the approval by the U.S. Food and Drug Administration (FDA) of Ramipril, an oral formulation of the antihypertensive, under ANDA No. 077626. This regulatory clearance is expected to significantly expand Lupin's profitability by providing a cost-effective, generic alternative to the brand-name drug, potentially disrupting market share dynamics within the cardiovascular therapy sector.